Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer

#ad
Random House #ad - Her-2 is a story of dramatic discoveries and strong personalities, ego, corporate decisions, politics, money, showing the combination of scientific investigation, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Unlike chemotherapy or radiation, Herceptin has no disabling side effects.

Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment.

Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer #ad - It marks the beginning of a new era of treatment for all kinds of cancers. Robert bazell presents a riveting account of how Herceptin was born. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. It works by inactivating her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors.

Then she took part in Genentech's clinical trials for a new drug. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had.

#ad



Genentech: The Beginnings of Biotech Synthesis

#ad
University of Chicago Press #ad -  . In the fall of 1980, Genentech, Inc. Became the overnight darling of wall Street, a little-known California genetic engineering company, raising over $38 million in its initial public stock offering. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise.

Drawing from an unparalleled collection of interviews with early biotech players, depicting Genentech’s improbable creation, Sally Smith Hughes offers the first book-length history of this pioneering company, precarious youth, and ascent to immense prosperity. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history.

Genentech: The Beginnings of Biotech Synthesis #ad - By placing genentech’s founders, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, venture capital, and with government regulation, followers, opponents, and commercial profits. Integrating the scientific, and the personal, the corporate, Genentech tells the story of biotechnology as it is not often told, the contextual, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science.

#ad



The Antidote: Inside the World of New Pharma

#ad
Simon & Schuster #ad - Werth described the company’s tumultuous early days during the AIDS crisis in The Billion-Dollar Molecule, a celebrated classic of science and business journalism. Werth captures the full scope of Vertex’s twenty-five-year drive to deliver breakthrough medicines. He provides a groundbreaking close-up of the upstart pharmaceutical company Vertex and the ferocious but indispensable world of Big Pharma that it inhabits.

In 1989, the charismatic joshua boger left Merck, then America’s most admired business, to found a drug company that would challenge industry giants and transform health care. In this timely and much praised book, Barry Werth draws upon inside reporting that spans more than two decades. Now he returns to tell a riveting story of Vertex’s bold endurance and eventual success.

The Antidote: Inside the World of New Pharma #ad - It’s riskier and more rigorous at just about every stage than any other business, from the towering biological uncertainties inherent in its mission to treat disease; to the 30-to-1 failure rate in bringing out a successful medicine even after a molecule clears all the hurdles to get to human testing; to the multibillion-dollar cost of ramping up a successful product; to operating in the world’s most regulated industry, matched only by nuclear power.

The $325 billion-a-year pharmaceutical business is America’s toughest and one of its most profitable. At a time when america struggles to maintain its innovative edge, The Antidote is a powerful inside look at one of the most intriguing and important business stories of recent decades.

#ad



The Billion-Dollar Molecule: The Quest for the Perfect Drug

#ad
Simon & Schuster #ad - Join journalist barry werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by joshua boger, vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, a dynamic Harvard- and Merck-trained scientific whiz kid, and a drug to combat the virus that causes AIDS.

You will be hooked from start to finish, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where obsessive, where the wheeling and dealing takes on a life of its own, as you go from the labs, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.

#ad



The Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Life-Saving Treatment

#ad
The Experiment #ad - A scientist scrutinizing a single human cell detects a missing piece of DNA. A chronicle of scientific rigor and determination, The Philadelphia Chromosome celebrates a rare triumph in the battle against cancer while offering a blueprint for future research. One of the wall street journal’s 10 Best Nonfiction Books of 2013.

The discovery of a cancer-causing genetic mutation leads to a lifesaving miracle drug in this “absorbing, complex medical detective story” Kirkus Reviews. Philadelphia, 1959. In 1990, chronic myeloid leukemia, the Philadelphia chromosome was recognized as the sole cause of a deadly blood cancer, or CML.

The Philadelphia Chromosome: A Genetic Mystery, a Lethal Cancer, and the Improbable Invention of a Life-Saving Treatment #ad - Cancer research would never be the same. With extensive research and numerous personal interviews, science journalist Jessica Wapner reconstructs the decades-long journey from Hungerford’s discovery to a breakthrough, lifesaving treatment. That scientist, david hungerford, has just stumbled on the starting point of modern cancer research?the Philadelphia chromosome.

It would take doctors and researchers around the world more than three decades to unravel the implications of this landmark discovery.

#ad



The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines

#ad
Evelexa Press #ad - Developing life-changing drugs is risky and expensive—but that’s not what makes them unaffordable. Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need.

Do we really have to choose between affordability and innovation?In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced by the healthcare system’s commitment to making those drugs affordable for all patients—a Biotech Social Contract.

The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines #ad - Through deep research and compelling stories of breakthroughs and breakdowns, including:why doesn’t insurance make drugs affordable?how can we prevent price-jacking of older drugs?Why are drugs more expensive in America than elsewhere?How can we guarantee that all medicines eventually go generic so they are only temporarily expensive?What systemic failures led to the opioid crisis, encouraging investment, and how can we prevent the next one?The Great American Drug Deal offers clear-eyed scrutiny of all players in the industry and examines vital ideas for closing loopholes, dealing with bad actors,  Kolchinsky presents solutions for striking a balance that are bold yet realistic and tackle today’s most pressing questions, and educating consumers.

It’s time we resolve to support patients and fuel discoveries that ease suffering now and for generations to come.

#ad



Drugs: From Discovery to Approval

#ad
Wiley-Blackwell #ad - Biotechnology is a dynamic field with changes across R&D, clinical trials, manufacturing and regulatory processes, and the third edition of the text provides timely updates for those in this rapidly growing field. The third edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, regulatory controls, the conduct of human clinical trials, and even the manufacturing processes for pharmaceutical products.

Drugs: From Discovery to Approval #ad - Concise and easy to read, drugs: from discovery to Approval, Third Edition quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. The third edition incorporates the latest developments and updates in the pharmaceutical community, provides more comprehensive coverage of topics, and includes more materials and case studies suited to college and university use.

#ad



Miracle Cure: The Creation of Antibiotics and the Birth of Modern Medicine

#ad
Penguin Books #ad - By 1955, the age-old evolutionary relationship between humans and microbes had been transformed, trivializing once-deadly infections. William rosen captures this revolution with all its false starts, lucky surprises, and eccentric characters. The epic history of how antibiotics were born, saving millions of lives and creating a vast new industry known as Big Pharma.

As late as the 1930s, virtually no drug intended for sickness did any good; doctors could set bones, deliver babies, and offer palliative care. Organizing that research needs large, built around the pharmaceutical company, and so our entire scientific-industrial complex, well-funded organizations and businesses, was born.

Timely, technology, combining science, and eye-opening, engrossing, politics, Miracle Cure is a must-read science narrative—a drama of enormous range, and economics to illuminate the reasons behind one of the most dramatic changes in humanity’s relationship with nature since the invention of agriculture ten thousand years ago.

Miracle Cure: The Creation of Antibiotics and the Birth of Modern Medicine #ad - He explains why, systematic, given the complex nature of bacteria—and their ability to rapidly evolve into new forms—the only way to locate and test potential antibiotic strains is by large-scale, trial-and-error experimentation. That all changed in less than a generation with the discovery and development of a new category of medicine known as antibiotics.

#ad



The Breakthrough: Immunotherapy and the Race to Cure Cancer

#ad
Twelve #ad - The result is what many are calling cancer's "penicillin moment, " a revolutionary discovery in our understanding of cancer and how to beat it. In the breakthrough, new york times bestselling author of the good Nurse Charles Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science.

. Engaging. In Mr. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step-harnessing the wealth of new information to create modern and more effective patient therapies-is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease.

Groundbreaking, as told through the experiences of the patients, riveting, physicians, THE BREAKTHROUGH is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, and expertly told, and cancer immunotherapy researchers who are on the front lines.

The Breakthrough: Immunotherapy and the Race to Cure Cancer #ad - Graeber's hands, the evolution of immuno-oncology is both captivating and heartbreaking. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history. Allison and Tasuku Honjo. For decades, scientists have puzzled over one of medicine's most confounding mysteries: Why doesn't our immune system recognize and fight cancer the way it does other diseases, like the common cold?As it turns out, the answer to that question can be traced to a series of tricks that cancer has developed to turn off normal immune responses-tricks that scientists have only recently discovered and learned to defeat.

#ad



p53: The Gene that Cracked the Cancer Code

#ad
Bloomsbury Sigma #ad - If the mistake is irreparable and the rogue cell threatens to grow out of control, p53 commands the cell to commit suicide. And as the long-anticipated revolution in cancer treatment tailored to each individual patient's symptoms begins to take off at last, p53 remains at the cutting edge. This timely tale of scientific discovery highlights the tremendous recent advances made in our understanding of cancer, a disease that affects more than one in three of us at some point in our lives.

Known simply as p53, this gene constantly scans our cells to ensure that they grow and divide without mishap, as part of the routine maintenance of our bodies. If a cell makes a mistake in copying its DNA during the process of division, p53 stops it in its tracks, summoning a repair team before allowing the cell to carry on dividing.

p53: The Gene that Cracked the Cancer Code #ad - Through the personal accounts of key researchers, p53: the gene that Cracked the Cancer Code reveals the fascination of the quest for scientific understanding, the enthusiasm, as well as the huge excitement of the chase for new cures – the hype, the blind alleys, the lost opportunities, and the thrilling breakthroughs.

Cancer cannot develop unless p53 itself is damaged or prevented from functioning normally. Perhaps unsurprisingly, p53 is the most studied single gene in history. This book tells the story of medical science's mission to unravel the mysteries of this crucial gene, and to get to the heart of what happens in our cells when they turn cancerous.

All of us have lurking in our DNA a most remarkable gene, which has a crucial job – it protects us from cancer.

#ad



The Emperor of All Maladies: A Biography of Cancer

#ad
Scribner #ad - Mukherjee recounts centuries of discoveries, setbacks, training their wits against an infinitely resourceful adversary that, just three decades ago, victories, told through the eyes of his predecessors and peers, and deaths, was thought to be easily vanquished in an all-out “war against cancer. The book reads like a literary thriller with cancer as the protagonist.

The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with—and perished from—for more than five thousand years. The story of cancer is a story of human ingenuity, paternalism, but also of hubris, resilience, and perseverance, and misperception. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer.

The Emperor of All Maladies: A Biography of Cancer #ad - Riveting, and surprising, urgent, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. Winner of the pulitzer prize, profoundly humane “biography” of cancer—from its first documented appearances thousands of years ago through the epic battles in the twentieth century to cure, control, The Emperor of All Maladies is a magnificent, and now a documentary from Ken Burns on PBS, and conquer it to a radical new understanding of its essence.

Physician, researcher, siddhartha mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and award-winning science writer, and a biographer’s passion. From the persian queen atossa, whose greek slave may have cut off her diseased breast, Carla, to the nineteenth-century recipients of primitive radiation and chemotherapy to Mukherjee’s own leukemia patient, The Emperor of All Maladies is about the people who have soldiered through fiercely demanding regimens in order to survive—and to increase our understanding of this iconic disease.

#ad